Pfizer 2005 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2005 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

2005 Financial Report 13
Financial Review
Pfizer Inc and Subsidiary Companies
Revenues — Major Human Health Products
(MILLIONS OF DOLLARS) YEAR ENDED DEC. 31, % CHANGE
________________________________________________ ______________________
PRODUCT PRIMARY INDICATIONS 2005 2004 2003 05/04 04/03
Cardiovascular
and metabolic diseases:
Lipitor Reduction of LDL cholesterol $12,187 $10,862 $9,231 12 18
Norvasc Hypertension 4,706 4,463 4,336 53
Cardura Hypertension/Benign prostatic hyperplasia 586 628 594 (7) 6
Accupril/Accuretic Hypertension/Congestive heart failure 294 665 706 (56) (6)
Caduet Reduction of LDL cholesterol and hypertension 185 50 — 272 —
Central nervous system
disorders:
Zoloft Depression and certain anxiety disorders 3,256 3,361 3,118 (3) 8
Neurontin Epilepsy and post-herpetic neuralgia 639 2,723 2,702 (77) 1
Geodon/Zeldox Schizophrenia and acute manic or mixed episodes
associated with bipolar disorder 589 467 353 26 32
Xanax/Xanax XR Anxiety/Panic disorders 409 378 238 859
Aricept(a) Alzheimer’s disease 346 308 254 12 22
Lyrica Epilepsy, post-herpetic neuralgia and
diabetic peripheral neuropathy 291 13 — M+ *
Relpax Migraine headaches 233 169 85 38 99
Arthritis and pain:
Celebrex(b) Arthritis pain and inflammation, acute pain 1,730 3,302 1,883 (48) 75
Bextra(b) Arthritis pain and inflammation (61) 1,286 687 * 87
Infectious and respiratory
diseases:
Zithromax/Zmax Bacterial infections 2,025 1,851 2,010 9(8)
Zyvox Bacterial infections 618 463 181 33 156
Diflucan Fungal infections 498 945 1,176 (47) (20)
Vfend Fungal infections 397 287 200 38 44
Urology:
Viagra Erectile dysfunction 1,645 1,678 1,879 (2) (11)
Detrol/Detrol LA Overactive bladder 988 904 544 966
Oncology:
Camptosar Metastatic colorectal cancer 910 554 299 64 86
Ellence Breast cancer 367 344 216 759
Aromasin Breast cancer 247 143 58 73 145
Ophthalmology:
Xalatan/Xalacom Glaucoma and ocular hypertension 1,372 1,227 668 12 84
Endocrine disorders:
Genotropin Replacement of human growth hormone 808 736 481 10 53
All other:
Zyrtec/Zyrtec-D Allergies 1,362 1,287 1,338 6(4)
Alliance revenue(c) Alzheimer’s disease (Aricept), neovascular (wet)
age-related macular degeneration (Macugen),
Parkinson’s disease (Mirapex), hypertension
(Olmetec), multiple sclerosis (Rebif) and
chronic obstructive pulmonary disease (Spiriva) 1,065 721 759 48 (5)
(a) Represents direct sales under license agreement with Eisai Co., Ltd.
(b) Includes direct sales under license agreement with Pharmacia prior to the acquisition.
(c) Includes alliance revenue for Celebrex and Bextra under co-promotion agreements with Pharmacia prior to the acquisition.
M+ Change greater than one-thousand percent.
*Calculation not meaningful.